Ritter Pharmaceuticals, Inc., a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance ...
In recent news, Allergan will be purchasing Kythera Biopharmaceuticals for $2.1 billion. With...
The acquisition further diversifies Tribute's product portfolio in Canada through the addition...
Target will sell its pharmacy and clinic businesses to the drugstore chain for about $1.9 billion in a deal that combines the resources of two retailers seeking to polish their health care reputations.
Cardinal Health will use existing cash and new debt to purchase the distributor.
Perrigo will acquire a portfolio of well-established over-the-counter brands from GlaxoSmithKline Consumer Healthcare.
Lannett Company announced that it has completed the acquisition of privately held Silarx Pharmaceuticals - a manufacturer and marketer of liquid generic pharmaceutical products.
Zimmer Holdings, Inc. announced today that it has finalized agreements with buyers to divest in the United States certain Zimmer Unicompartmental High-Flex Knee System assets, Biomet Discovery Elbow System assets and CobaltT bone cement assets.
Zimmer Holdings announced that it has finalized agreements with buyers to divest their own assets, as well as those of Biomet and Cobalt.
The buyout adds another major revenue producer to Abbvie's portfolio, which already includes the world's top-selling drug, Humira.
"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.
A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium ...
Tribute Pharmaceuticals Canada Inc., a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that its wholly owned subsidiary ...
Investors started shedding Achillion shares early Wednesday, less than a day after the drugmaker announced a partnership with pharmaceutical giant Johnson & Johnson that snuffed out the prospect of a near-term acquisition. Achillion and Johnson & Johnson's Janssen Pharmaceutical Companies ...
CVS Health will spend more than $10 billion to buy pharmacy services provider Omnicare and tap a growing target for prescription drug distribution: care for the elderly. The deal announced Thursday will give one of the nation's biggest pharmacy benefits ...
US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par Pharma by TPG to Endo was announced on Monday. The US Pharma industry has seen 39 deals valued at US$ 77.3bn to-date, three more deals announced ...
Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and ...
Endo International will spend about $8.05 billion to acquire Par Pharmaceutical as it pushes further into the generic drug market. Endo CEO Rajiv De Silva said the deal make Endo one of the top five generics companies as measured by U.S. sales.
Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.
Eli Lilly and Company and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies.
ProPharma Group, a compliance services company, today announced its acquisition of PROSAR, a provider of pharmacovigilance and medical information services.
Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.
Juno Therapeutics, a biopharmaceutical company focused on cancer treatment, announced today that it has acquired Stage Cell Therapeutics GmbH.
Endo International has acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas.
BASF recently announced plans to sell several prominent pharmaceutical ingredients to Siegfried Holding AG for $306 million.
The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.
MorphoSys AG announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
Alexion Pharmaceuticals will pay a huge premium to buy fellow rare disease treatment maker Synageva BioPharma in an $8.4-billion deal for a company with no products on the market.
- Page 1